Melanotan I

FDA Approved

Also known as: Afamelanotide, CUV1647, Scenesse

Prescription Only — FDA Approved Medication

Educational Content Only

This information is for educational purposes only and does not constitute medical advice, diagnosis, or treatment. The FDA has not evaluated many of the peptides discussed here. Always consult a licensed healthcare provider before making any health decisions.

Overview

Melanotan I (afamelanotide) is a synthetic alpha-melanocyte-stimulating hormone (alpha-MSH) analogue that is FDA-approved (as Scenesse) for the prevention of phototoxicity in adult patients with erythropoietic protoporphyria (EPP). Unlike Melanotan II, it has a more selective pharmacological profile without the erectile and appetite effects seen with non-selective analogues.

Possible Uses

The following areas have been examined in research contexts. This does not constitute medical advice or imply proven efficacy in humans.

Skin & Wound Healing

Mechanism of Action

Acts as an agonist at melanocortin 1 receptor (MC1R) on melanocytes, stimulating eumelanin synthesis and increasing skin pigmentation, which reduces phototoxic injury in EPP patients. The selective MC1R profile reduces off-target melanocortin receptor activation.

Safety Notes

FDA-approved (Scenesse) for EPP. Adverse effects include nausea, flushing, and injection site reactions. Changes in pre-existing nevi have been observed and require monitoring. Prescription only.

Want to learn more?

Ask Research Chat about Melanotan I

Research Profile

Half-Life

~15-40 hours (subcutaneous implant formulation)

Administration

subcutaneous implant (approved form)

Legal Status (US)

FDA-approved prescription medication (Scenesse) for EPP.

43 indexed research passages

Related Peptides

Tropisetron

Tropisetron is a 5-HT3 receptor antagonist and alpha7 nicotinic acetylcholine receptor agonist approved in various countries for chemotherapy-induced nausea. Research has also examined its potential roles in pain management, fibromyalgia, and cognitive enhancement through its dual receptor pharmacology.

KPV

KPV is a tripeptide derived from the C-terminal sequence of alpha-melanocyte-stimulating hormone (α-MSH). Research has examined its potent anti-inflammatory properties, particularly in gut epithelial models and inflammatory bowel disease research.

Larazotide

Larazotide is a synthetic octapeptide that acts as a tight junction regulator in gut epithelium. Research has examined its potential to reduce intestinal permeability ('leaky gut') in celiac disease and other inflammatory gut conditions by antagonizing the zonulin pathway.

Clascoterone

Clascoterone is a topical androgen receptor antagonist and the first FDA-approved topical androgen receptor inhibitor, approved for the treatment of acne vulgaris. Research has also examined its potential for androgenetic alopecia given its local antiandrogen activity without the systemic hormonal effects of oral antiandrogens.